Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.53 |
| ▸ | TBK1 | Q9UHD2 | 13/20 | 0.49 |
| ▸ | MLLT1 | Q03111 | 1/20 | 0.49 |
| ▸ | F10 | P00742 | 1/20 | 0.48 |
| ▸ | DRD4 | P21917 | 1/20 | 0.47 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.47 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.47 |
| ▸ | BACE1 | P56817 | 1/20 | 0.47 |
| ▸ | VEGFA | P15692 | 1/20 | 0.47 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23932558 | 0.86 | RPS6KB1 (0.55) | TBK1HRH4 | |
| SCHEMBL25180592 | 0.83 | LMNA (0.56) | LMNAMLLT1F10DRD4HRH4 | |
| SCHEMBL31569732 | 0.81 | TBK1 (0.44) | LMNATBK1DRD4BACE1 | |
| SCHEMBL23932528 | 0.79 | KMT2A (0.52) | TBK1DRD4HRH4HRH3VEGFA | |
| SCHEMBL6420823 | 0.78 | BACE1 (0.47) | LMNAF10HRH4HRH3BACE1 | |
| SCHEMBL30083799 | 0.77 | TBK1 (0.59) | TBK1 | |
| SCHEMBL28634875 | 0.77 | MAPT (0.52) | LMNADRD4 | |
| SCHEMBL7016134 | 0.76 | PARP1 (0.45) | TBK1DRD4VEGFAEGLN1 | |
| SCHEMBL29111354 | 0.76 | GAA (0.66) | LMNADRD4 | |
| SCHEMBL5536182 | 0.76 | VEGFA (0.68) | DRD4VEGFAEGLN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230150980-A1 | COLLAGEN 1 TRANSLATION INHIBITORS AND METHODS OF USE THEREOF | ANIMA BIOTECH INC. (US) | 2023-05-18 | — | — | US | disclosed |
| US-20230150980-A1 | COLLAGEN 1 TRANSLATION INHIBITORS AND METHODS OF USE THEREOF | ANIMA BIOTECH INC. (US) | 2023-05-18 | — | — | US | disclosed |
| US-20230150980-A1 | COLLAGEN 1 TRANSLATION INHIBITORS AND METHODS OF USE THEREOF | ANIMA BIOTECH INC. (US) | 2023-05-18 | — | — | US | disclosed |
| EP-4139291-A1 | COLLAGEN 1 TRANSLATION INHIBITORS AND METHODS OF USE THEREOF | Anima Biotech Inc. (US) | 2023-03-01 | — | — | EP | disclosed |
| CN-115427404-A | Collagen 1 translation inhibitors and methods of use thereof | 艾尼莫生物科技公司 | 2022-12-02 | — | — | CN | disclosed |
| WO-2021216665-A9 | COLLAGEN 1 TRANSLATION INHIBITORS AND METHODS OF USE THEREOF | ANIMA BIOTECH INC. (US) | 2021-12-02 | — | — | WO | disclosed |
| WO-2021216665-A1 | COLLAGEN 1 TRANSLATION INHIBITORS AND METHODS OF USE THEREOF | ANIMA BIOTECH INC. (US) | 2021-10-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230150980-A1 | COLLAGEN 1 TRANSLATION INHIBITORS AND METHODS OF USE THEREOF | COL1A1, COL2A1, COL14A1 | LMNA 575/4885TBK1 1782/4885MLLT1 3760/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.